Abstract
In diabetic retinopathy, treatment is indicated for sight-threatening complications like proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DME). For decades, treatment has been with panretinal laser for PDR and focal/grid laser for DME. In recent years, intravitreal therapy with vascular endothelial growth factor (VEGF) inhibition or steroids has replaced laser treatment in centre-involving DME. Intravitreal VEGF-inhibition has also demonstrated effectiveness in PDR, but long-term studies are needed to address the concern of a potential continuous treatment burden.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / therapeutic use
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use
-
Diabetes Mellitus, Type 1 / complications
-
Diabetes Mellitus, Type 2 / complications
-
Diabetic Retinopathy* / drug therapy
-
Diabetic Retinopathy* / etiology
-
Diabetic Retinopathy* / prevention & control
-
Diabetic Retinopathy* / surgery
-
Humans
-
Intravitreal Injections
-
Laser Coagulation
-
Macular Edema* / drug therapy
-
Macular Edema* / etiology
-
Macular Edema* / prevention & control
-
Macular Edema* / surgery
Substances
-
Angiogenesis Inhibitors
-
Anti-Inflammatory Agents